SCHEMBL4628443

SCHEMBL4628443

N=C(NCCCCc1ccccc1)NC(=O)c1cccs1

nearest known ligand 0.70

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.70
CYP1A2 P05177 1/20 0.70
CYP2C9 P11712 1/20 0.70
CYP2C19 P33261 1/20 0.70
SMN1; SMN2 Q16637 6/20 0.61
RAB9A P51151 5/20 0.61
SCN5A Q14524 1/20 0.59
SCN2A Q99250 1/20 0.59
KDM4E B2RXH2 2/20 0.54
HPGD P15428 2/20 0.52
HTT P42858 1/20 0.48
MAPT P10636 1/20 0.48
POLB P06746 2/20 0.47
USP2 O75604 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
GAA P10253 1/20 0.47
TRPV1 Q8NER1 1/20 0.47
HSP90AA1 P07900 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4628469 0.91 NPC1 (0.74) NPC1CYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL711885 0.87 NPC1 (0.91) NPC1CYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL4629277 0.83 NPC1 (0.57) NPC1CYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL4628427 0.81 KMT2A (0.63) NPC1CYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL4629466 0.81 NPC1 (0.65) NPC1SMN1; SMN2RAB9ASCN5ASCN2A
SCHEMBL4627518 0.79 POLB (0.60) NPC1SMN1; SMN2RAB9ASCN5ASCN2A
SCHEMBL4628740 0.79 KDM4E (0.55) NPC1CYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL11276433 0.77 NPC1 (1.00) NPC1CYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL4628683 0.76 SCN5A (0.58) NPC1SMN1; SMN2RAB9ASCN5ASCN2A
SCHEMBL4628956 0.76 HPGD (0.76) NPC1SMN1; SMN2RAB9ASCN5ASCN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1032556-B1 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE WYETH CORP (US) 2007-12-19 EP claimed
US-7041702-B1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-05-09 US claimed
EP-1918272-A1 Pharmaceutically active compounds and methods of use Wyeth a Corporation of the State of Delaware (US) 2008-05-07 EP disclosed
EP-1032556-B1 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE WYETH CORP (US) 2007-12-19 EP disclosed
US-20060270741-A1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-11-30 US disclosed
US-7041702-B1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270741-A1 Pharmaceutically active compounds and methods of use GBA1, CTSA, GAA NPC1 140/4885CYP1A2 1959/4885CYP2C9 683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.